Arvinas to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Arvinas, a clinical-stage biotechnology company focused on targeted protein degradation, will participate in two upcoming investor conferences. The Cowen 43rd Annual Health Care Conference is scheduled for March 6, featuring a fireside chat with Chief Medical Officer Ron Peck and Senior VP Randy Teel. A live audio webcast will be available here. The Oppenheimer 33rd Annual Healthcare Conference will be held on March 13, with the same speakers and similar webcast availability here.

NEW HAVEN, Conn., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in two upcoming investor conferences:

• Cowen 43^rd Annual Health Care Conference on Monday, March 6. Ron Peck, M.D., Chief Medical Officer, and Randy Teel, Ph.D., Senior Vice President, Corporate and Business Development, will participate in a fireside chat. A live audio webcast of the presentation will be available here and on the Events + Presentations section of the Company’s website.
  
  
• Oppenheimer 33rd Annual Healthcare Conference on Monday, March 13. Ron Peck, M.D., Chief Medical Officer, and Randy Teel, Ph.D., Senior Vice President, Corporate and Business Development, will participate in a fireside chat. A live audio webcast of the presentation will be available here and on the Events + Presentations section of the Company’s website.
  

About Arvinas
Arvinas is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC® Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC® targeted protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. In addition to its robust preclinical pipeline of PROTAC® protein degraders against validated and “undruggable” targets, the company has three investigational clinical-stage programs: bavdegalutamide (ARV-110) and ARV-766 for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471 for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. For more information, visit www.arvinas.com. 

Contacts

Investors:
Jeff Boyle
+1 (347) 247-5089
Jeff.Boyle@arvinas.com

Media:
Kirsten Owens
+1 (203) 584-0307
Kirsten.Owens@arvinas.com

FAQ

What are the upcoming investor conferences for Arvinas in March 2023?

Arvinas will participate in the Cowen 43rd Annual Health Care Conference on March 6, and the Oppenheimer 33rd Annual Healthcare Conference on March 13, 2023.

Who from Arvinas will be speaking at the investor conferences?

Ron Peck, M.D., Chief Medical Officer, and Randy Teel, Ph.D., Senior Vice President, Corporate and Business Development, will speak at both conferences.

How can I access the webcasts of the Arvinas conferences?

Live audio webcasts of the Arvinas presentations can be accessed through their official website or directly via the webcast links for each conference.

What drug development focuses does Arvinas have?

Arvinas focuses on therapies for diseases by degrading disease-causing proteins, using its proprietary PROTAC® Discovery Engine platform.

What are the investigational programs of Arvinas?

Arvinas has investigational programs for ARV-110 and ARV-766 for metastatic castration-resistant prostate cancer and ARV-471 for ER+/HER2- breast cancer.